TCM‐Guided Targeted Therapies Against NLRP3 Inflammasome in NAFLD
Immunity, Inflammation and Disease · 2026-06 · 14 (6)
DOI: 10.1002/iid3.70474 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 17.06.2026. Verfasst von Yanxia Zhang. Beteiligte Einrichtung: Shandong Xinzhonglu Traditional Chinese Medicine Hospital, Jinan, Shandong, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Non-alcoholic Fatty Liver Disease, Inflammasomes, Medicine, Chinese Traditional. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Xinzhonglu Traditional Chinese Medicine Hospital.
Abstract (Originalsprache)
Background
Non‐alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder driven by inflammation, in which the NLRP3 inflammasome plays a central role. Current targeted inhibitors face challenges in patient stratification and long‐term safety.
Methods
A narrative literature review was conducted using PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), and Google Scholar from database inception to February 2026. Search terms included combinations of “non‐alcoholic fatty liver disease”, “NAFLD”, “NASH”, “NLRP3 inflammasome”, “traditional Chinese medicine”, “TCM”, “herbal medicine”, “syndrome differentiation”, and “precision medicine”. Peer‐reviewed original articles, systematic reviews, and clinical studies addressing NLRP3 in NAFLD or TCM‐based interventions targeting this pathway were prioritized.
Results
TCM syndrome patterns (e.g., damp‐heat, phlegm‐damp) correlate with distinct NLRP3 activation states and inflammatory phenotypes. Herbal compounds such as berberine and curcumin, as well as classical TCM formulae, exert multi‐target effects by suppressing NLRP3 inflammasome assembly, enhancing antioxidant defenses, and modulating the gut‐liver axis. Based on this evidence, we propose an integrative “TCM Syndrome–NLRP3 Molecular Endotype–Precision Targeted Therapy” model that links specific TCM syndromes to canonical, non‐canonical, or sustained NLRP3 activation, thereby providing hypothesis‐driven strategies for personalized intervention.
Discussion
This integrative framework bridges TCM holistic principles with modern inflammasome biology. It provides a theoretical basis for personalized, biomarker‐driven NAFLD therapies, highlighting the synergy between traditional medicine and precision hepatology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shandong Xinzhonglu Traditional Chinese Medicine Hospital, Jinan, Shandong, China.
ORCID-Profile: Yanxia Zhang
Förderung
- Shandong Xinzhonglu Traditional Chinese Medicine Hospital
Zitieren
APA
Zhang, Y. (2026). TCM‐Guided Targeted Therapies Against NLRP3 Inflammasome in NAFLD. Immunity, Inflammation and Disease, 14(6). https://doi.org/10.1002/iid3.70474
Vancouver
Zhang Y. TCM‐Guided Targeted Therapies Against NLRP3 Inflammasome in NAFLD. Immunity, Inflammation and Disease. 2026;14(6). doi:10.1002/iid3.70474
BibTeX
@article{Zhang2026,
author = {Zhang, Yanxia},
title = {TCM‐Guided Targeted Therapies Against NLRP3 Inflammasome in NAFLD},
journal = {Immunity, Inflammation and Disease},
year = {2026},
volume = {14},
number = {6},
doi = {10.1002/iid3.70474}
}
EUVIMED